B lymphocytes as effector cells in the immunotherapy of cancer
dc.contributor.author | Namm, Jukes P. | en_US |
dc.contributor.author | Li, Qiao | en_US |
dc.contributor.author | Lao, Xiangming | en_US |
dc.contributor.author | Lubman, David M. | en_US |
dc.contributor.author | He, Jintang | en_US |
dc.contributor.author | Liu, Yashu | en_US |
dc.contributor.author | Zhu, Jianhui | en_US |
dc.contributor.author | Wei, Shuang | en_US |
dc.contributor.author | Chang, Alfred E. | en_US |
dc.date.accessioned | 2012-03-16T16:00:21Z | |
dc.date.available | 2013-05-01T17:24:41Z | en_US |
dc.date.issued | 2012-03-15 | en_US |
dc.identifier.citation | Namm, Jukes P.; Li, Qiao; Lao, Xiangming; Lubman, David M.; He, Jintang; Liu, Yashu; Zhu, Jianhui; Wei, Shuang; Chang, Alfred E. (2012). "B lymphocytes as effector cells in the immunotherapy of cancer." Journal of Surgical Oncology 105(4): 431-435. <http://hdl.handle.net/2027.42/90339> | en_US |
dc.identifier.issn | 0022-4790 | en_US |
dc.identifier.issn | 1096-9098 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90339 | |
dc.description.abstract | Over the years, the role of B cells in the host immune response to malignancy has been overshadowed by our focus on T cells. Nevertheless, B cells play important roles as antigen‐presenting cells and in the production of antibodies. Furthermore, B cells can function as effector cells that mediate tumor destruction on their own. This review will highlight the various functions of B cells that are involved in the host response to tumor. J. Surg. Oncol. 2012;105:431–435. © 2011 Wiley Periodicals, Inc. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | B Cells | en_US |
dc.subject.other | Tumor Antigen | en_US |
dc.subject.other | Adoptive Immunotherapy | en_US |
dc.subject.other | Antibody | en_US |
dc.title | B lymphocytes as effector cells in the immunotherapy of cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | 3302 Cancer Center, 1500 E. Medical Center Dr., Ann Arbor, MI 48109. Fax: 734‐647‐9647. | en_US |
dc.contributor.affiliationother | Sun Yat‐sen University Cancer Center & State Key Laboratory of Oncology in Southern China, Guangzhou, China | en_US |
dc.contributor.affiliationother | Department of Surgery, Loma Linda University, Loma Linda, California | en_US |
dc.identifier.pmid | 21898417 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90339/1/22093_ftp.pdf | |
dc.identifier.doi | 10.1002/jso.22093 | en_US |
dc.identifier.source | Journal of Surgical Oncology | en_US |
dc.identifier.citedreference | Schultze JL, Michalak S, Seamon MJ, et al.: CD40‐activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen‐specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100: 2757 – 2765. | en_US |
dc.identifier.citedreference | Mizoguchi A, Bhan AK: A case for regulatory B cells. J Immunol 2006; 176: 705 – 710. | en_US |
dc.identifier.citedreference | Mauri C, Ehrenstein MR: The 'short' history of regulatory B cells. Trends Immunol 2008; 29: 34 – 40. | en_US |
dc.identifier.citedreference | Vetrie D, Vorechovsky I, Sideras P, et al.: The gene involved in X‐linked agammaglobulinaemia is a member of the src family of protein‐tyrosine kinases. Nature 1993; 361: 226 – 233. | en_US |
dc.identifier.citedreference | Tsukada S, Saffran DC, Rawlings DJ, et al.: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X‐linked agammaglobulinemia. Cell 1993; 72: 279 – 290. | en_US |
dc.identifier.citedreference | Bacchelli C, Buckridge S, Thrasher AJ, et al.: Translational mini‐review series on immunodeficiency: Molecular defects in common variable immunodeficiency. Clin Exp Immunol 2007; 149: 401 – 409. | en_US |
dc.identifier.citedreference | Brodt P, Gordon J: Anti‐tumor immunity in B lymphocyte‐deprived mice. I. Immunity to a chemically induced tumor. J Immunol 1978; 121: 359 – 362. | en_US |
dc.identifier.citedreference | Monach PA, Schreiber H, Rowley DA: CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 1993; 55: 1356 – 1361. | en_US |
dc.identifier.citedreference | Chapoval AI, Fuller JA, Kremlev SG, et al.: Combination chemotherapy and IL‐15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell‐mediated effects antagonized by B cells. J Immunol 1998; 161: 6977 – 6984. | en_US |
dc.identifier.citedreference | Qin Z, Richter G, Schuler T, et al.: B cells inhibit induction of T cell‐dependent tumor immunity. Nat Med 1998; 4: 627 – 630. | en_US |
dc.identifier.citedreference | Perricone MA, Smith KA, Claussen KA, et al.: Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother (1997) 2004; 27: 273 – 281. | en_US |
dc.identifier.citedreference | Shah S, Divekar AA, Hilchey SP, et al.: Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti‐tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005; 117: 574 – 586. | en_US |
dc.identifier.citedreference | Inoue S, Leitner WW, Golding B, et al.: Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006; 66: 7741 – 7747. | en_US |
dc.identifier.citedreference | Watt V, Ronchese F, Ritchie D: Resting B cells suppress tumor immunity via an MHC class‐II dependent mechanism. J Immunother (1997) 2007; 30: 323 – 332. | en_US |
dc.identifier.citedreference | Joao C, Ogle BM, Gay‐Rabinstein C, et al.: B cell‐dependent TCR diversification. J Immunol 2004; 172: 4709 – 4716. | en_US |
dc.identifier.citedreference | Crowley MT, Reilly CR, Lo D: Influence of lymphocytes on the presence and organization of dendritic cell subsets in the spleen. J Immunol 1999; 163: 4894 – 4900. | en_US |
dc.identifier.citedreference | Moulin V, Andris F, Thielemans K, et al.: B lymphocytes regulate dendritic cell (DC) function in vivo: Increased interleukin 12 production by DCs from B cell‐deficient mice results in T helper cell type 1 deviation. J Exp Med 2000; 192: 475 – 482. | en_US |
dc.identifier.citedreference | DiLillo DJ, Yanaba K, Tedder TF: B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010; 184: 4006 – 4016. | en_US |
dc.identifier.citedreference | von Bergwelt‐Baildon MS, Vonderheide RH, Maecker B, et al.: Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40‐activated B cells as antigen‐presenting cells: Potential for clinical application. Blood 2002; 99: 3319 – 3325. | en_US |
dc.identifier.citedreference | Kondo E, Topp MS, Kiem HP, et al.: Efficient generation of antigen‐specific cytotoxic T cells using retrovirally transduced CD40‐activated B cells. J Immunol 2002; 169: 2164 – 2171. | en_US |
dc.identifier.citedreference | Lapointe R, Bellemare‐Pelletier A, Housseau F, et al.: CD40‐stimulated B lymphocytes pulsed with tumor antigens are effective antigen‐presenting cells that can generate specific T cells. Cancer Res 2003; 63: 2836 – 2843. | en_US |
dc.identifier.citedreference | Coughlin CM, Vance BA, Grupp SA, et al.: RNA‐transfected CD40‐activated B cells induce functional T‐cell responses against viral and tumor antigen targets: Implications for pediatric immunotherapy. Blood 2004; 103: 2046 – 2054. | en_US |
dc.identifier.citedreference | Van den Bosch GA, Ponsaerts P, Nijs G, et al.: Ex vivo induction of viral antigen‐specific CD8 T cell responses using mRNA‐electroporated CD40‐activated B cells. Clin Exp Immunol 2005; 139: 458 – 467. | en_US |
dc.identifier.citedreference | Chung Y, Kim BS, Kim YJ, et al.: CD1d‐restricted T cells license B cells to generate long‐lasting cytotoxic antitumor immunity in vivo. Cancer Res 2006; 66: 6843 – 6850. | en_US |
dc.identifier.citedreference | Tamada K, Harada M, Okamoto T, et al.: Specific antitumor activity of tumor‐infiltrating lymphocytes expanded first in a culture with both anti‐CD3 monoclonal antibody and activated B cells and then in a culture with interleukin‐2. Cancer Immunol Immunother 1995; 41: 339 – 347. | en_US |
dc.identifier.citedreference | Harada M, Okamoto T, Kurosawa S, et al.: The antitumor activity induced by the in vivo administration of activated B cells bound to anti‐CD3 monoclonal antibody. Cell Immunol 1995; 161: 132 – 137. | en_US |
dc.identifier.citedreference | Kawakami K, Terabe M, Kawakami M, et al.: Characterization of a novel human tumor antigen interleukin‐13 receptor alpha2 chain. Cancer Res 2006; 66: 4434 – 4442. | en_US |
dc.identifier.citedreference | Li Q, Teitz‐Tennenbaum S, Donald EJ, et al.: In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 2009; 183: 3195 – 3203. | en_US |
dc.identifier.citedreference | Li Q, Lao X, Pan Q, et al.: Adoptive transfer of tumor reactive B cells confers host T‐cell immunity and tumor regression. Clin Cancer Res 2011 17: 4987 – 4995. | en_US |
dc.identifier.citedreference | Kemp TJ, Moore JM, Griffith TS: Human B cells express functional TRAIL/Apo‐2 ligand after CpG‐containing oligodeoxynucleotide stimulation. J Immunol 2004; 173: 892 – 899. | en_US |
dc.identifier.citedreference | Lopez DM, Blomberg BB, Padmanabhan RR, et al.: Nuclear disintegration of target cells by killer B lymphocytes from tumor‐bearing mice. FASEB J 1989; 3: 37 – 43. | en_US |
dc.identifier.citedreference | LeBien TW, Tedder TF: B lymphocytes: How they develop and function. Blood 2008; 112: 1570 – 1580. | en_US |
dc.identifier.citedreference | Fagraeus A: The plasma cellular reaction and its relation to the formation of antibodies in vitro. J Immunol 1948; 58: 1 – 13. | en_US |
dc.identifier.citedreference | Cooper MD, Peterson RD, Good RA: Delineation of the thymic and bursal lymphoid systems in the chicken. Nature 1965; 205: 143 – 146. | en_US |
dc.identifier.citedreference | Cooper MD, Raymond DA, Peterson RD, et al.: The functions of the thymus system and the bursa system in the chicken. J Exp Med 1966; 123: 75 – 102. | en_US |
dc.identifier.citedreference | Ron Y, De Baetselier P, Gordon J, et al.: Defective induction of antigen‐reactive proliferating T cells in B cell‐deprived mice. Eur J Immunol 1981; 11: 964 – 968. | en_US |
dc.identifier.citedreference | Ron Y, Sprent J: T cell priming in vivo: A major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol 1987; 138: 2848 – 2856. | en_US |
dc.identifier.citedreference | Janeway CA, Jr., Ron J, Katz ME: The B cell is the initiating antigen‐presenting cell in peripheral lymph nodes. J Immunol 1987; 138: 1051 – 1055. | en_US |
dc.identifier.citedreference | Lanzavecchia A: Antigen‐specific interaction between T and B cells. Nature 1985; 314: 537 – 539. | en_US |
dc.identifier.citedreference | Harris DP, Haynes L, Sayles PC, et al.: Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 475 – 482. | en_US |
dc.identifier.citedreference | Harris DP, Goodrich S, Mohrs K, et al.: Cutting edge: the development of IL‐4‐producing B cells (B effector 2cells) is controlled by IL‐4, IL‐4 receptor alpha, and Th2 cells. J Immunol 2005; 175: 7103 – 7107. | en_US |
dc.identifier.citedreference | Harris DP, Goodrich S, Gerth AJ, et al.: Regulation of IFN‐gamma production by B effector 1 cells: Essential roles for T‐bet and the IFN‐gamma receptor. J Immunol 2005; 174: 6781 – 6790. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.